BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Endothelial cell
,
Neocentromeres
,
Fenofibrate
,
rs2300478
,
CYP51
,
Leukemia
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
TIM)-1
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for TIM)-1
Explore Curated Studies Results
Literature
Most Relevant Literature
KIM-1 augments hypoxia-induced tubulointerstitial inflammation through uptake of small extracellular…
T-Cell Immunoglobulin and Mucin Domain 1 (TIM-1) Is a Functional Entry Factor for Tick-Borne Encepha…
Kidney injury molecule-1 and podocalyxin dysregulation in an arginine vasopressin induced rodent mod…
Malate reduced kidney injury molecule (KIM-1) expression and selectively upregulated the renal nitri…
Tim-1 Deficiency Aggravates High-Fat Diet-Induced Steatohepatitis in Mice.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participa…
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-0…
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ